

Verteporfin, YAP inhibitor; Anticancer activity

Catalog	Unit
TBI3487-5MG	5 mg
TBI3487-25MG	25 mg

Product Details

Formal Name: (4R,4aS)-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester

Alternate Names: CL 318,952; BPD-MA

Molecular Formula: C₄₁H₄₂N₄O₈

Formula Weight: 718.80

CAS Number: 129497-78-5


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 14 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.



Applications

YAP inhibitor; Anticancer activity

Functions

Photosensitive drug used to ablate unwanted neovascularity in the eye, esophageal mucosa, and elsewhere using light to create damaging free radicals and high-molecular-weight crosslinked oligomers. Independent of light exposure, verteporfin inhibits transcription by YAP/TAZ (via disruption of YAP-TEAD interaction) (IC₅₀ = 2.5 μM), inhibiting autophagy and halting proliferation of cancer and cancer stem cell lines. Inhibits autophagosome formation. Reverses differentiation of Src-overexpressing embryonic stem cells, and blocks SARS-CoV-2 infection in vitro and in vivo.

Application Procedures

First dissolved in DMSO (up to 14 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

For research use only.